AMELIA MANGUNE: Open Payments
NPI 1316656473 · RENO, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,512 in 56 payments from 11 companies in 2025. Trend: 2023 $841 · 2024 $646 · 2025 $1,512
Food & beverage: $1,412Education: $100
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 13 | $518 |
| ABBVIE INC. | 29 | $498 |
| GENZYME CORPORATION | 2 | $141 |
| Phathom Pharmaceuticals, Inc. | 3 | $134 |
| QOL Medical, LLC | 3 | $82 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $30 |
| Ipsen Biopharmaceuticals, Inc | 1 | $25 |
| Aimmune Therapeutics, Inc. | 1 | $25 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $22 |
| Madrigal Pharmaceuticals | 1 | $19 |
Products named: TREMFYA, RINVOQ, DUPIXENT, VOQUEZNA, SKYRIZI, MAVYRET, Sucraid, CREON.
Industry payments across NV — which companies pay providers there.
